Biofutures Share Discussion Threads

[madmick] 10/3/2013 13:12

he probably meant 7p leeds
but that was the take over price not the placing price.
There will no more shares on the market tomorrow than when it went into suspension.
just another one talking tosh.

[leedskier] 10/3/2013 13:05

The placing is actually at 140p ...

"8. Details of the Placing
The Company is seeking to raise £32.5 million (before expenses) by way of the Placing. Pursuant to the Placing Agreement, Panmure Gordon has conditionally placed 23,214,286 Placing Shares with institutional investors on behalf of the Company at the Placing Price. The Placing Shares will represent approximately
19.9 per cent. of the Enlarged Share Capital. On Admission, the Company will have a market capitalisation of approximately £163.2 million based on the Placing Price."

[leedskier] 10/3/2013 13:03

There aren't any.

If you are referring to those holding unlisted Platinum shares.

[snatander] 10/3/2013 12:40

"Lock-In Persons" Platinum Energy Global Sdn.
Bhd., Rampai Teknologi Sdn.
Bhd., Green Ethics Capital
Sdn. Bhd., Lim Ted Hing,
Quek Siew Hau, Chan Ka Tsung,
Fong Tham Yu, Seah Sen Onn
@ David Seah, Dato' Jespal
Deol Balbir Singh, Dato'
Mohd Sallehuddin bin Othman,
Tan Sri Dato' Sri Abi Musa
Asa'ari Bin Mohamed Nor,
Anbananthan Shanmugam, Dato'
Larry Gan Nyap Liou @ Gan
Nyap Liow, Dato' Foong Choong
Heng, Sushil Singh Sidhu
Joginder Singh, Dr Wong
Kai Fatt, David John Long,
Dr Patrick Dennis Howes,
MSG Commercial, Oceanair
Environmental, Cyril Tan
Eng Wah, Asia Bioenergy
Research, Leung Kok Keong,
Ubud Consortium and Plug
& Play Technology





And what about the non lock in persons?

[snatander] 10/3/2013 12:35

placing at 70p
Doesnt have own IP only a licence to use the IP
Shareholder list looks weak expectng the malaysians to sell into the market

[leedskier] 10/3/2013 08:54

KEY STATISTICS

Existing Unconsolidated Ordinary Shares 166,445,000


Proposed Share Consolidation ratio

1 new Consolidated Ordinary Share for every 20 Existing Unconsolidated Ordinary Shares


Number of Consolidated Ordinary Shares in issue immediately after 8,322,250 the Share Consolidation and prior to the issue of the Consideration Shares
and the Placing Shares

Number of Consideration Shares being issued pursuant to the Acquisition 85,000,000

Number of Placing Shares being issued pursuant to the Placing 23,214,286

Placing Price 140 pence Gross proceeds raised by the Placing £32.5 million Net proceeds raised by the Placing £30.0 million Number of Consolidated Ordinary Shares in issue on Admission 116,536,536
Percentage of Enlarged Share Capital represented by the:

• Consideration Shares 72.9 per cent.

• Placing Shares 19.9 per cent.

• Existing Unconsolidated Ordinary Shares 7.1 per cent. Market capitalisation of the Company at the Placing Price at Admission £163.2 million TIDM up to Admission BIP TIDM from Admission GRPH ISIN Number up to Admission GB00B12B4T47
ISIN Number from Admission GB00B9BBJ076

5

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Publication of the Admission Document and notice of GM 8 March 2013

Re-commencement of dealings on AIM in the Existing 11 March 2013
Unconsolidated Ordinary Shares

Latest time and date for receipt of completed Forms of Proxy for the GM 10.00 a.m. on 21 March 2013

Record date for the Share Consolidation 25 March 2013

General Meeting 10.00 a.m. on 25 March 2013

Completion of the Acquisition 26 March 2013

Admission effective and expected commencement of dealings on AIM 8.00 a.m. on 26 March 2013 in the Enlarged Share Capital

Expected date for CREST accounts to be credited in respect 26 March 2013 of the Consideration Shares and the Placing Shares

Adjustment to CREST accounts in respect of the Consolidated 26 March 2013
Ordinary Shares

Despatch of definitive share certificates in respect of the Consolidated 8 April 2013
Ordinary Shares by no later than

Biofutures website: www.biofuturesplc.com Platinum Group website: www.platinumgroup.com.my Enlarged Group website from Admission: www.graphenenanochem.com

6

DIRECTORS, PROPOSED DIRECTORS, SECRETARY AND ADVISERS

Directors Dr Wong Kai Fatt (Chief Executive Officer)
Dr Patrick Dennis Howes (Non-executive Chairman) David John Long (Non-executive Director)

Proposed Directors Tan Sri Abi Musa (Proposed Non-executive Chairman) Dato' Larry Gan (Proposed Non-executive Director) Alan Cleverly OBE (Proposed Non-executive Director) Dato' Jespal Deol (Proposed Chief Executive Officer) Sushil Sidhu (Proposed Chief Financial Officer)

Company Secretary David John Long all of:
Registered Office Academy House London Road Camberley
Surrey GU15 3HL


Nominated Adviser to the
Company, up to Admission




Broker and Sole Bookrunner to the Company and, from Admission, Nominated Adviser and Broker to the Company

Daniel Stewart & Company plc
Becket House
36 Old Jewry
London EC2R 8DD

Panmure Gordon (UK) Limited
One New Change
London EC4M 9AF


Reporting Accountants Crowe Clark Whitehill LLP Crowe Horwath Advisory Sdn. Bhd.
St. Bride's House Level 13A Tower C
10 Salisbury Square Megan Avenue II
London EC4Y 8EH 12 Jalan Yap Kwan Seng
50450 Kuala Lumpur
Malaysia

Legal Advisers to the Company as to English law


Legal Advisers to the Company as to Malaysian law





Legal Advisers to Daniel
Stewart and Panmure Gordon

Duane Morris & Selvam LLP
16, Collyer Quay, # 17-00
Singapore 049318

Song & Partners
No. 51-1, Jalan Medang Serai
Bukit Bandaraya
59100 Kuala Lumpur
Malaysia

Travers Smith LLP
10 Snow Hill
London EC1A 2AL


Registrars Share Registrars Limited
Suite E First Floor
9 Lion and Lamb Yard
Farnham
Surrey GU9 7LL

[leedskier] 10/3/2013 08:16

I have converted the Admission Document from pdf to MS Word and uploaded that part of it containing the Chairman's letter to the scroll box in the post above. (edit) More parts follow ...

[leedskier] 10/3/2013 08:14

PART 1

LETTER FROM THE CHAIRMAN

Biofutures International plc
(Registered and incorporated in England and Wales No. 05712979)

Directors: Registered Office:
Dr Patrick Dennis Howes (Non-executive Chairman) Academy House Dr Wong Kai Fatt (Chief Executive Officer) London Road David John Long (Non-executive Director) Camberley Surrey GU15 3HL

Proposed Directors:
Tan Sri Abi Musa Dato' Larry Gan Alan Cleverly OBE Dato' Jespal Deol Sushil Sidhu

8 March 2013

Dear Shareholder,

Acquisition of Platinum NanoChem Sdn. Bhd.
Share Consolidation
Placing of 23,214,286 Placing Shares at 140 pence per share Application for Admission of the Enlarged Share Capital to AIM Change of name to Graphene NanoChem Plc
Amendments to Articles of Association Approval of New Long Term Incentive Plan and
Notice of General Meeting


1. Introduction
On 10 December 2012, the Company announced that it had entered into a conditional agreement to acquire Platinum NanoChem, a company involved in the development and production of speciality chemicals and advanced nanomaterials. The consideration for the Acquisition will be satisfied through the issuance of the Consideration Shares (representing approximately 72.9 per cent. of the Enlarged Share Capital) to the Vendors. Further details of the Acquisition are set out below in paragraph 5 of this Part 1 and in paragraph
8.1 of Part 8 of this document.

The Acquisition constitutes a reverse takeover under the AIM Rules and is therefore conditional, inter alia, upon the approval of Shareholders at the General Meeting. Such approval is being sought at the General Meeting which will be held at Academy House, London Road, Camberley, Surrey at 10.00 a.m. on 25 March
2013. Notice of the General Meeting is set out in at the end of this document. Resolutions will also be proposed at the General Meeting to consolidate the Company's share capital on a 1 for 20 basis.

In order to provide the Enlarged Group with sufficient funds to implement its expansion strategy and for its working capital purposes, pursuant to the Placing Agreement, Panmure Gordon, as agent for the Company, has conditionally placed 23,214,286 Placing Shares on behalf of the Company at the Placing Price. The Placing Shares will represent approximately 19.9 per cent. of the Enlarged Share Capital and will raise approximately £32.5 million (approximately £30.0 million net of expenses) for the Company. The Placing is underwritten by Panmure Gordon. At the Placing Price, the Company will have a market capitalisation of




16

approximately £163.2 million on Admission. Further details of the Placing are set out below in paragraph 8 of this Part 1 and in paragraph 8 of Part 8 of this document.

If the Resolutions are passed at the General Meeting, and the other conditions set out in the Acquisition Agreement and Placing Agreement are satisfied or waived, Admission will occur following the completion of the Acquisition, which is expected to occur on 26 March 2013.

The Existing Unconsolidated Ordinary Shares were suspended from trading on AIM on 10 December 2012 and have remained suspended pending the publication of this document. The Existing Unconsolidated Ordinary Shares are expected to be restored to trading on AIM with effect from 7.30 a.m. on 11 March 2013. Trading in the Existing Unconsolidated Ordinary Shares will be cancelled immediately prior to Admission. It is expected that Admission will occur on 26 March 2013.

On Completion of the Acquisition, Tan Sri Abi Musa, Dato' Larry Gan, Alan Cleverly, Dato' Jespal Deol and Sushil Sidhu will join the board of the Company as further described in paragraph 7 of this Part 1.

In addition, resolutions will be proposed at the General Meeting to change the name of the Company to
Graphene NanoChem Plc and to approve the New LTIP and changes to the Articles.

The purpose of this document is to (i) provide you with the background to, reasons for and details of the Acquisition (ii) explain why the Directors consider the Proposals to be in the best interests of the Company and its Shareholders as a whole, and (iii) seek Shareholder approval for the Resolutions.

This document also contains the Directors' recommendation that you vote in favour of the Resolutions to be proposed at the GM convened for 10.00 a.m. on 25 March 2013, as the Board has irrevocably undertaken to do. Shareholders should note that the Resolutions (apart from Resolution 6) are inter-conditional upon one another and consequently, if any of Resolutions 1 to 5 or Resolution 7 is not passed, the Acquisition, the Placing and Admission will not occur. The Directors and certain Shareholders (including Henderson Global Investors Limited, Stoutman Holdings Limited and AXA Investment Managers UK Limited) have irrevocably undertaken to vote in favour of the Resolutions at the General Meeting in respect of their beneficial holdings, which amount in aggregate to 76,106,410 Existing Unconsolidated Ordinary Shares representing 45.7 per cent. of the Existing Unconsolidated Ordinary Shares.

You should read the whole of this document and your attention in particular is drawn to the risk factors set out in Part 4 of this document.


2. Platinum Group
The Platinum Group is a privately held global nanotechnology company whose business model is to design, formulate, manufacture and market a range of Graphene-enhanced speciality chemicals and advanced materials that demonstrate improved performance characteristics when compared to existing products within the chemicals and materials markets. It has a revenue-generating range of high quality chemical products derived from readily available low-cost wastes from the palm oil industry, alongside an active commercialisation strategy for niche opportunities within the global market for Graphene applications. Its existing portfolio and pipeline of products are based on two core nanotechnology platforms which are protected by a network of patent families, licences and specialist knowledge. The Group's strong and experienced management team has significant technical and business experience and a successful track record.

Graphene is an emerging class of nanomaterial with a wide range of intrinsic properties, from enhanced electrical and thermal conductivity to exceptional mechanical load bearing capacity and performance. This enables the creation of innovative products with the potential to revolutionise a range of industries, including fuels, lubricants, oilfield chemicals, composites, energy generation and storage, electronics and medical devices.

Since inception, the strategy of the Platinum Group has been to build an independent, high-margin, public company, based on proprietary and defensible intellectual property, through the supply of waste-based, high-performance cost-competitive products into global growth markets, with blue-chip international



17

customers and development partners. The Platinum Group selected Malaysia as its base primarily because of an abundant source of palm waste for feedstock, access to the mandated Malaysian biofuels market, government support for high-technology industries and sound economic prospects, both nationally and in the wider South East Asian region. Its planned next stage of development is to use its speciality chemicals business as a solid cash-generating foundation for the Enlarged Group, whilst aiming to maximise the opportunities presented by the Enlarged Group's ability to manufacture Graphene affordably at commercial scale. The New Board has no plans for the Platinum Group to become a volume supplier of Graphene to third parties. It will focus on the development of proprietary applications of Graphene in areas where it believes that it is possible to deploy Graphene-enhanced products in bulk, to provide solutions to pressing problems in large and high-value markets. The Enlarged Group's first Graphene-enhanced products are expected to enter the market in July 2013.

The Platinum Group transitioned from a research and development group focused on technology and product development to a commercial operating group in 2012. Operations are conducted from the Platinum Group's Platinum Nanotek Park located in Senawang, Malaysia which currently houses an 90 million litres per annum speciality chemicals plant and a 1,000 kg per annum Graphene plant. Despite working capital constraints, the Platinum Group's speciality chemicals business generated sales of approximately
£16.3 million in the eleven months to 30 November 2012 through sales to, inter alia, blue chip multinational oil and gas companies, including Chevron and Shell.

The New Board believes that Graphene enhancement will drive higher margins for the Enlarged Group's speciality chemicals business. The Platinum Group has a contract to supply its Graphene-enhanced drilling fluids in July 2013 to Scomi Group, the fourth largest drilling fluids supplier globally. The New Board expects to launch a surfactant range of products in 2013, which when coupled with the Platinum Group's planned lightweight Graphene-enhanced proppant, are anticipated to achieve significant inroads into the rapidly growing shale exploration market.

In parallel to its planned 250,000 kg per annum Graphene plant capacity expansion, the Group is developing its advanced nanomaterials business, focusing on engineering plastics, enhanced composites and renewable energy components, addressing markets estimated to reach US$76.8 billion by 2017 (Source: Global Engineering Plastics Market Analysis by Product Types, Applications & Geography – Trends & Forecasts (2012–2017), Markets and Markets). In addition, the Platinum Group's strategy of developing a licensing and joint venture business model within other sectors of the substantial addressable markets for Graphene-enabled products, underpinned by the revenue generation and existing infrastructure of the speciality chemicals business, aims to provide the Enlarged Group with growing high-quality revenue streams and increased shareholder value. The Platinum Group has entered into confidentiality agreements with leading multinational companies and aims to convert these into joint ventures, licensing and product development agreements in the near to medium term.

Platinum NanoChem has invested approximately £39 million in developing and building platform nanotechnologies and an asset base that enables production of speciality performance chemicals and advanced nanomaterials through a combined acquisition and development strategy.

The Platinum Group's current products and pipeline are based on two core nanotechnology platforms, namely its SimPlat cavitation and Catalyx nanomaterials processes.

The SimPlat Process is currently applied primarily in the production of high performance esters for various applications, including second generation biofuels, drilling fluids and surfactants for the oil and gas and consumer markets. Products are sold to customers serving large, global markets with significant performance, regulatory and environmental drivers. In addition, owing to the use of low-cost waste as feedstock, some of the issues faced by the producers of first generation biofuels, namely high prices and volatility of food-grade feedstocks and the negative publicity surrounding the use of food for fuel are less relevant to the Platinum Group. The Catalyx Process enables the production of a family of Graphene nanomaterials including nanoplatelets, nanotubes, nanochips and nanofibres with addressable markets in excess of €2 trillion by 2015 (Source: Chemicals, REACH and Nanomaterials).





18

The New Board considers that the Group's innovative approach to its nanomaterial technology platform, a diversified portfolio of products and the broad range of applications for Graphene-enhanced materials, combined with a cash-generative platform of its existing speciality chemicals, provides the Enlarged Group with the opportunity to generate growing revenue streams and shareholder value.


3. Background to and reasons for the Proposals
The Biofutures Group is focused on the conversion of CPO into refined bleached and deodorised palm oil ("RBDPO") at its 14-acre site in the Palm Oil Industrial Cluster in Lahad Datu, Sabah, East Malaysia. Recent high prices of CPO in Malaysia, particularly in relation to the CPO price in neighbouring Indonesia have impacted Biofutures' prospects severely. This has made the Biofutures Group's key product, RBDPO, uncompetitive in the regional market. Consequently, Biofutures has for some time been considering a variety of options for strengthening the business and improving shareholder value.

The Directors believe that the Acquisition offers an opportunity to enhance shareholder value and move Biofutures from its current position, which suffers from considerable exposure to volatile commodity prices, into the manufacture of added-value products with higher margins. The Directors believe that the Acquisition and subsequent retrofitting of the Biofutures Group's Zurex Refinery with the Platinum Technologies (as described in paragraph 3 of Part 2) offer Biofutures the opportunity to achieve high levels of growth from diversified sources of revenue whilst diversifying the risks to which the business is subject.

The Zurex Refinery located in the POIC region offers:

(1) an advantageous location for the expansion of the Platinum Group's speciality chemicals business.
The Zurex Refinery is well located to source feedstock from the local region, which includes both East Malaysia and Kalimantan, Indonesia. It is also well placed to access the East Malaysian market for biofuels, which is currently undersupplied owing to a shortage of local production and the cost of transportation from West Malaysia;

(2) a ready-made asset and infrastructure base, including access to a deep-water port to serve the export markets for the Platinum Group's speciality chemicals business. This is expected to reduce the need for extensive plant construction time and cost, thus accelerating growth of the Platinum Group's business and improving operational efficiency; and

(3) the benefit of Zurex's existing licences, the acquisition of which can be a time-consuming and costly process.

The New Board believes that the Acquisition and the Placing will result in an enlarged integrated business that has a strong business model, sustainable revenue streams and robust growth prospects in the near and long term and which will effectively de-risk the Biofutures Group's current business operations.


4. Key Strengths of the Enlarged Group
The New Board believes that the key strengths of the Enlarged Group will include:

• Technology: A portfolio of integrated technologies, with IP protection, that permit the production of high value chemicals and advanced nanomaterials from readily available and lower-cost feedstocks;

• Market opportunity: The Enlarged Group's products will target multi-billion dollar global markets with substantial economic and regulatory drivers;

• Team: A strong and experienced management team and staff with significant technical and business expertise, and a successful track record, in relevant industry sectors;

• Pipeline and customer base: The Enlarged Group will have substantial existing demand for its portfolio of speciality chemicals from blue-chip multinational customers and an advanced pipeline of uses for the future production of its advanced nanomaterials;





19

• Sustainability: The Enlarged Group's products will assist its partners to reduce carbon intensity, reduce waste and reduce water pollution; and

• Government backing: The Enlarged Group benefits from the support of the Malaysian government, including an equity investment from a Government of Malaysia linked fund, debt facilities provided by two government-backed financial institutions, a government-backed debt guarantee for the proposed Graphene plant expansion, favourable tax structures and subsidised fuel markets.


5. Principal Terms of the Acquisition
Under the terms of the Acquisition Agreement, the Company has conditionally agreed to acquire the entire issued share capital of Platinum NanoChem from the Vendors for a total consideration to be satisfied by the issue of the Consideration Shares (representing 72.9 per cent. of the Enlarged Share Capital) on Admission.

During the period between the date of the execution of the Acquisition Agreement and Completion, the Majority Vendors undertook to procure and ensure that the Platinum Group carries on its business in the normal and ordinary course in a manner not inconsistent with the Platinum Group's ordinary business practice. The Acquisition Agreement contains customary warranties (subject to customary limitations of liability) and undertakings given by the Vendors in favour of the Company.

Completion of the Acquisition is conditional, inter alia, on the passing of Resolutions 1, 2 and 3 as set out in the Notice of General Meeting at the end of this document. Subject to the conditions being satisfied or waived, Completion is expected to take place upon Admission.

Further details of the Acquisition Agreement are set out in paragraph 8.1 of Part 8 of this document.


6. Share Consolidation
The Company's Existing Unconsolidated Ordinary Shares have a nominal value of £0.01 (1 pence) each. When trading in the Existing Unconsolidated Ordinary Shares was suspended on 10 December 2012, the price of each Existing Unconsolidated Ordinary Share was 3.1 pence. A reorganisation of the Existing Unconsolidated Ordinary Share Capital is proposed whereby each holding of 20 Existing Unconsolidated Ordinary Shares will be consolidated into one Consolidated Ordinary Share. Resolution 4 will effect the Share Consolidation.

Holders of fewer than 20 Existing Unconsolidated Ordinary Shares will not be entitled to receive a
Consolidated Ordinary Share following the Share Consolidation. Shareholders with a holding in excess of
20 Existing Unconsolidated Ordinary Shares, but which is not exactly divisible by 20, will have their holding of Consolidated Ordinary Shares rounded down to the nearest whole number of Consolidated Ordinary Shares following the Share Consolidation. Fractional entitlements to Consolidated Ordinary Shares will be aggregated and the resulting new Consolidated Ordinary Shares will be sold in the market and the proceeds will be retained for the benefit of the Company.

The Existing Unconsolidated Ordinary Shares have been admitted to CREST. Application will be made for the Enlarged Share Capital to be admitted to CREST, all of which may then be held and transferred by means of CREST. It is expected that the Consolidated Ordinary Shares arising as a result of the Share Consolidation will be credited to the relevant CREST accounts on 26 March 2013.

The record date of the Share Consolidation is 25 March 2013. The rights attaching to the Consolidated
Ordinary Shares will be identical in all respects to those of the Existing Unconsolidated Ordinary Shares.

New share certificates will be issued to holders of Existing Unconsolidated Ordinary Shares following the Share Consolidation. Pending the issue of these new share certificates, existing share certificates in respect of Existing Unconsolidated Ordinary Shares existing share certificate(s) will remain valid.

The Company's existing share options will be adjusted to take account of the Share Consolidation as set out in paragraph 9.1.5 of Part 8 of this document.





20

7. Directors, Proposed Directors and Senior Management
Brief biographies of the Directors, the Proposed Directors and senior management of the Enlarged Group are set out below. Paragraph 4 of Part 8 of this document sets out further details of current and past directorships and certain other important information regarding the New Board.

Current Directors
Dr Patrick Dennis Howes (Aged 58), Non-executive Chairman
Patrick Howes holds a Ph.D. in Chemistry from Salford University in the synthesis and properties of a class of nanomaterials utilised in the oil and gas industries. His previous experience includes catalyst development with a joint-venture between UOP, a multi-national company developing and delivering technology to the oil and gas industries, and Johnson Matthey plc. He also worked for Laporte Industries plc, the second largest chemical company in the U.K. and the Taiko Group. He is the founder of Iceni Chemicals International, a process-plant design consultancy and trading house, and a director of Natural Bleach Sdn Bhd, developing and marketing novel, environmentally-friendly clay products for the refining of edibile oils, and re-refining of used mineral oils. He is Chairman of the Remuneration Committee.


Dr ("Joe") Wong Kai Fatt (Aged 48), Chief Executive Officer
Joe Wong holds a degree in computer science and a Ph.D. in Pharmacy and Healthcare Administration (1991) from the University of Louisiana. He is currently on the board of Boots The Chemist Sdn. Bhd. and a number of other companies. Prior to this, he held a number of senior roles in the financial services sector and has published works in the area of healthcare and equity investment.


David John Long (Aged 66), Non-executive Director
David Long has had many years' experience in operational management and business accounting processes, particularly within the paints and coatings industry. He was the General Manager of Hampton Paints, the specialist paint and chemical company. Previously he was at Berger Paints and Ameron International Corporation, prior to which he spent 13 years at International Paint, now part of AKZO Nobel, the global paints and coatings business. He was Finance and Administration Director of Perfect Images Limited, a print and printing ink supplier. David Long has a degree in business management. He is currently the Chairman of the Audit Committee.

From Admission, it is intended that Dr Patrick Howes and Dr Joe Wong will step down as Non-executive Chairman of the board and Chief Executive Officer of the Enlarged Group respectively but will continue as Non-executive and Executive Directors respectively.

Proposed Directors

Tan Sri Dato' Sri Abi Musa Asa'ari Bin Mohamed Nor (Aged 63), Proposed Non-executive Chairman
Abi Musa joined the Platinum Board on 7 October 2006. Abi Musa has had a distinguished career in the Malaysian civil service, retiring as the Secretary General of the Ministry of Agriculture and Small Industries, Malaysia in September 2006. He started his career as an Assistant Director in the Public Service Department in 1973 and thereafter served in various capacities in the Malaysian civil service including as the Deputy Director, Petroleum Development Division under the Prime Minister's Department, Deputy Director, Budget Division of the Ministry of Finance and the Director General of the Federal Agriculture Marketing Authority, Malaysia. His current roles include serving as Non-executive Chairman of the Malaysian Pilgrimage Funds Board, with more than US$9 billion in assets under management, as Non-executive Chairman of Pelikan International, a global inks company, and as an Independent Non-executive Director of HeiTech Padu Berhad, a Malaysian ICT company listed on the Main Board of Bursa Malaysia. Abi Musa is also the Chairman of the Malaysian Biodiesel Association and of the Sultan Idris Education University.

Abi Musa holds an MBA from the University of Birmingham, and an undergraduate degree in economics from the University of Malaya.




21

Dato' Jespal Singh Deol Balbir Singh (Aged 47), Proposed Chief Executive Officer
Jespal Deol joined the Platinum Board on 6 October 2006 and was the co-founder of Platinum NanoChem. He was appointed as the Managing Director of Platinum NanoChem in January 2007. Jespal was previously the co-founder and the Executive Director of Corporate and Business Development of Stevian Biotechnology, a biotechnology company involved in the production of natural-based sweetener from stevia, which was admitted to trading on AIM as Pure Circle Limited in December 2007 at a market capitalisation of £384 million. At Stevian Biotechnology, Jespal was instrumental in securing its development funding and closing global sales with multinational customers. Jespal is a solicitor by training and was the founding partner of Deol & Gill, specialising in corporate mergers and acquisitions. Jespal also serves as an independent non-executive director and chairman of the Audit Committee of IMU Education Sdn Bhd, which operates the International Medical University of Kuala Lumpur and is part of IHH Healthcare Berhad, which was dual-listed in Singapore and Malaysia in July 2012.

Jespal holds a Bachelor of Law degree from the University of Queensland, Australia.


Sushil Singh Sidhu Joginder Singh (Aged 47), Proposed Chief Financial Officer
Sushil joined the Platinum Board on 21 August 2006 and was the co-founder of Platinum NanoChem. He has been the executive director of finance of Platinum NanoChem since January 2007 and has more than 15 years of experience in corporate finance, equity capital markets and venture capital management. Prior to the Platinum Group, Sushil was the Finance Director of Stevian Biotechnology and was part of the management team that developed Stevian Biotechnology from its start-up position and raised its development funding. He was the former Chief Operating Officer of Commerce-Meridian Capital Sdn Bhd, a joint venture management company with the CIMB Group. Sushil has served with local and international financial houses including Southern Bank Securities, Jardine Matheson and Nikkei Pacific Corporate Advisory Sdn. Bhd.

Sushil holds a Bachelor's degree in Business (majoring in Finance) from Deakin University, Melbourne, Australia and an MBA (majoring in Finance) from the University of Hull. He is also a Senior Associate of the Institute of Credit Management, Australia and an Associate of the Institute of Bankers, Australia.


Alan Michael Cleverly, OBE (Aged 64), Proposed Non-executive Director
Alan currently serves as Parliamentary Agent to Rt Hon Michael Gove MP, the Secretary of State for Education, and is actively involved in various non-profit organisations in support of small and medium enterprises and corporate governance practices. Alan is the is the founder and Chief Executive Officer of the Genesis Initiative, a non-profit body that represents the interests of UK Small and Medium Enterprises. He was the former director and company secretary to the Corporate Governance Forum Limited and currently serves as Events Facilitator to the All Party Parliamentary Corporate Governance Group.


Dato' Larry Gan Nyap Liou @ Gan Nyap Liow (Aged 58), Proposed Non-executive Director
Larry spent 26 years with Accenture, the world's leading consulting firm, during which time he held many global leadership roles, consulted on strategic projects for multinational corporations, and worked with innovative technologies around the world. He was Accenture's Managing Partner for Asia, and between 1999 to 2003 he managed the firm's multi-billion dollar Venture Fund in Asia Pacific and concluded investments in China, Japan, Australia and Singapore.

He served as Chairman of the Association of Computer Industry Malaysia, Vice-President of the Association of Asian Oceania Computer Industry Organisation, and a Member of the Minister of Science & Technology Think Tank, Copyright Tribunal, Labuan International Financial Exchange Committee, MIMOS Berhad (Government Technology Research) and the Malaysia US Business Council.

He is currently Chairman of Cuscapi and Diversified Gateway Solutions Berhad, and holds a number of other directorships. He is also Chairman of the British Malaysian Chamber of Commerce and a Board Member of the Minority Shareholder Watchdog Group. Larry is a chartered accountant and a certified management consultant.




22

Key Management

Anbananthan Shanmugam (Aged 40), Proposed Chief Operating Officer
Anbath was appointed Chief Operating Officer of the Platinum Group in February 2013. Prior to that, he held the post of Chief Executive Officer of Platinum GreenChem, responsible for the speciality chemicals business of the Platinum Group. He has been with the Platinum Group since incorporation. Anbath has more than 15 years' experience in business development and operations management in the manufacturing and telecommunications industries. Prior to Platinum Group, he was the General Manager of Stevian Biotechnology, responsible for the management of strategic international accounts, operations, logistics and supply chain integration for the business. Anbath has also served with the Sapura Group and Maxis Communications.

Anbath holds a Bachelor degree in Business Administration from the University of Malaya, Malaysia.


Juzermoiz Jangbarwala (Aged 53), Proposed Chief Technology Officer
Juzer was appointed Chief Technology Officer of the Platinum Group in January 2011. As the Chief Executive Officer of Catalyx Nanotech Inc. Mr Jangbarwala was instrumental in developing the Catalyx process. He founded the technology incubator Catalyx Inc. in 2002, which has had five successful spinoffs prior to Catalyx Nanotech Inc. He served as Chief Technology Officer of Sustainable Environmental Technologies Corporation until April 2009. Before that he founded Hydromatix, Inc. in 1989, which was acquired by the BOC Group in 2002, and served as its President, Chief Executive Officer and Chief Technology Officer. He has a proven track record of identifying a need in the market place in the field of chemical engineering, developing a commercially feasible product to service that need and putting a technical team together to commercialise the product.

The New Board has also identified a new Head of Advanced Nanomaterials, with 15 years of directly relevant experience. It is intended that he will join the Enlarged Group shortly after Admission.


8. Details of the Placing
The Company is seeking to raise £32.5 million (before expenses) by way of the Placing. Pursuant to the Placing Agreement, Panmure Gordon has conditionally placed 23,214,286 Placing Shares with institutional investors on behalf of the Company at the Placing Price. The Placing Shares will represent approximately
19.9 per cent. of the Enlarged Share Capital. On Admission, the Company will have a market capitalisation of approximately £163.2 million based on the Placing Price.

The Placing Shares will be in registered form and will be issued credited as fully paid and will, on issue, rank pari passu in all respects with the Existing Unconsolidated Ordinary Shares in issue prior to Admission, including the right to receive all dividends and other distributions thereafter declared, made or paid on the Existing Unconsolidated Ordinary Shares. The Existing Unconsolidated Ordinary Shares were created under the Act and can be issued in certificated or uncertificated form.

The Placing Agreement is conditional, inter alia, upon Resolutions 1 to 5 being passed at the General Meeting and Admission becoming effective by 8.00 a.m. on 26 March 2013 or such later date (being no later than 8.00 a.m. on 30 April 2013) as the Company and Panmure Gordon may agree. The Placing is underwritten by Panmure Gordon.

Panmure Gordon has a right to terminate the Placing Agreement prior to Admission in certain circumstances, including a breach of warranty, a material adverse change in the Platinum Group or the Biofutures Group or the occurrence of force majeure.

Further details of the Placing Agreement are set out in paragraph 8.4 of Part 8 of this document.

23

9. Use of Proceeds
The net proceeds of the Placing, amounting to approximately £30.0 million, will be used to:

• increase the capacity of the Platinum Group's existing speciality chemicals plant from 90 to
136 million litres per annum, including for the production of commercial quantities of PlatQuat
(£6 million);

• increase the capacity of the Platinum Group's existing advanced nanomaterials plant from 1,000 to
250,000 kg per annum, through Platinum NanoChem's subscription for further ordinary shares in
Platinum Nano G (£6 million);

• fund technology commercialisation and Graphene applications development efforts (£4 million);

• increase the size and breadth of the Enlarged Group's intellectual property portfolio (£4 million);

• support development of joint venture initiatives (£4 million); and

• fund the Company's general working capital requirements (£6 million).

The New Board believes that the Acquisition, the Placing and Admission of the Enlarged Share Capital to trading on AIM will result in the Enlarged Group having:

• a fully funded expansion programme;

• a significantly strengthened balance sheet with sufficient flexibility for further expansion;

• the increased profile of a public listed company;

• a significantly improved position when negotiating joint ventures and development efforts; and

• the ability to issue the Consolidated Ordinary Shares as consideration for potential acquisitions and as a means of incentivising new and existing staff.


10. Strategy of the Enlarged Group
Since inception, the strategy of the Platinum Group has been to build an independent, high-margin, public company, based on proprietary and defensible intellectual property. The Platinum Group's strategic goals aim to exploit the global megatrend towards sustainability through the supply of waste-based, high-performance, cost-competitive products into global growth markets, with blue-chip international customers and development partners.

With the speciality chemicals business providing a solid foundation for the Enlarged Group, the New Board aims to maximise the opportunities presented by the Enlarged Group's ability to manufacture Graphene affordably at commercial scale. Despite the current scarcity of Graphene, the New Board has no plans for the Enlarged Group to be a volume supplier of Graphene to third parties. Instead, they will focus on the development of proprietary applications of Graphene in areas where they believe that it is possible to deploy Graphene-enhanced products in bulk, to provide solutions to pressing problems in large and high-value markets.

The New Board has identified oilfield chemicals and engineering plastics as being two core areas where enhancement with Graphene offers the possibility of creating products which have the potential to become market leaders in the near to medium term. In particular, they believe that PlatDrill, for offshore drilling, and PlatQuat, especially when allied to the Group's planned Graphene-enhanced proppant, for the growing shale oil & gas exploration market, have the potential to deliver significant high-margin revenue streams.

In order to produce the required volumes of the Group's speciality chemicals and Graphene, the New Board intends to use the proceeds of the Placing to increase the capacity of the Platinum Group's existing speciality chemicals plant from 90 to 136 million litres per annum, including for the production of commercial quantities of PlatQuat and to increase the capacity of the Platinum Group's existing advanced nanomaterials plant from 1,000 to 250,000 kg per annum. The New Board also intends to develop the Zurex Refinery into



24

a pre-treatment plant for a new speciality chemicals plant, with associated Graphene production, in the near to medium term.

Licensing strategy
Outside the core areas of oilfield chemicals and engineering plastics, the Enlarged Group will pursue a licensing model in a number of areas, where the Enlarged Group's supply of Graphene and knowledge in relation to its application are expected to translate into licence agreements. Compared to the pharmaceutical industry (where a licensing strategy has been pursued by many participants for several years), the industries which the Enlarged Group is targeting tend to be characterised by shorter and less costly product development timelines and lower regulatory hurdles prior to product launch.

IP strategy
While the New Board believes that the intellectual property underpinning the Platinum Group's production processes is strongly defensible, there exist a number of opportunities to file patents on applications of Graphene in a number of markets. Using the net proceeds of the Placing, the New Board intends to file a number of patents in key jurisdictions in relation to certain well-understood applications of Graphene nano materials. Much of the patent activity in the area to date has been focused on the high-value and complex applications of Graphene, with Samsung in particular filing a considerable number of patents, particularly in the Advanced Electronics area, from which substantial revenues are unlikely in the near term. Consequently, the Platinum Directors believe that there are considerable opportunities to acquire portfolios of patents in other areas, which, in the absence of commercial quantities of Graphene, are likely to be relatively inexpensive to acquire.

Acquisition strategy
In addition to acquisitions of IP, the New Board has identified a small number of companies whose staff base, IP, knowledge of Graphene applications and/or existing routes into target customers they believe could add substantial value to the Enlarged Group. With the Graphene industry still in its infancy, the New Board believes that such acquisitions will be relatively inexpensive to make, likely to be made principally using the Enlarged Group's shares as consideration and could offer transformative opportunities to the Enlarged Group.


11. Lock-In and Orderly Market Arrangements
At Admission, the New Board will hold or be interested in, directly and indirectly, an aggregate of
40,416,766 Consolidated Ordinary Shares, representing approximately 34.7 per cent. of the Enlarged Share Capital of the Company. This amount includes 28,736,563 Consolidated Ordinary Shares which will on Admission be held by Platinum Energy Global Sdn. Bhd., in which Dato' Jespal Deol will have an indirect interest through his 99.9 per cent. legal and beneficial interest in Total Platinum Holdings Sdn. Bhd. which holds a 69.3 per cent. interest in Platinum Energy Global Sdn. Bhd.

The Directors, Proposed Directors and the Vendors have agreed not to (and to use all reasonable endeavours to procure that their connected persons do not) dispose of any interest in the Consolidated Ordinary Shares, which they may have on Admission, or subsequently acquire within one year of Admission, comprising in aggregate 73.6 per cent. of the Enlarged Share Capital, for the period of one year following Admission except in certain restricted circumstances. In addition, they have each further agreed that for an additional twelve month period following the first anniversary of Admission, in order to ensure an orderly market in the Company's shares, they shall (and they shall use all reasonable endeavours to procure that their connected parties shall) only dispose of any interest in Consolidated Ordinary Shares in such manner as the Company's broker may reasonably require.

Stoutman Holdings Limited has agreed that for a 24 month period following Admission they shall only dispose of any interest in the Consolidated Ordinary Shares in such manner as the Company's broker may reasonably require.

Details of these lock-in and orderly market arrangements are set out in paragraph 8.5 of Part 8 of this document.


25

12. Dividend Policy
The Company is primarily seeking to achieve capital growth for Shareholders. It is the New Board's intention during the current phase of the Enlarged Group's development to retain future distributable profits from the business to the extent any are generated. Neither the Company nor any other member of the Enlarged Group has declared or paid any dividend in the period covered by the financial information set out in Parts 5 and 6 of this document. The New Board does not anticipate declaring any dividends in the foreseeable future but may recommend distributions at some future date depending upon the generation of sustainable profits when it becomes commercially prudent to do so.


13. Long term incentive plan
The New Board proposes, subject to Shareholders' approval, that the Company adopts the New LTIP to incentivise the New Board and senior management. Further details of the rules of the New LTIP are set out in paragraph 9.2 of Part 8 of this document. The New LTIP will supersede the Existing LTIP adopted by the Company at its extraordinary general meeting held on 23 November 2006.


14. Corporate Governance
The UK Corporate Governance Code applies only to companies on the Official List and not to companies admitted to trading on AIM. However, the New Board recognises the importance of sound corporate governance and intends that the Company will comply with the provisions of the QCA guidelines insofar as they are appropriate given the Company's size and stage of development.

The Board is responsible for formulating, reviewing and approving the Company's strategy, budgets and corporate actions. Following Admission, the Company intends to hold Board meetings at least six times each year and at other times as and when required.

The Company has established properly constituted audit and remuneration committees of the Board with formally delegated duties and responsibilities. New appointments to the Board will be considered by the Board as a whole.

The audit committee has primary responsibility for monitoring the quality of internal controls and ensuring that the financial performance of the Company is properly measured and reported on. It will receive and review reports from the Company's management and auditors relating to the interim and annual accounts and the accounting and internal control systems in use throughout the Company. The audit committee will meet not less than four times in each financial year and will have unrestricted access to the Company's auditors. The audit committee will, on Admission, comprise David Long, who will act as chairman of the committee, Tan Sri Abi Musa and Patrick Howes.

The remuneration committee will review the performance of the executive directors and make recommendations to the Board on matters relating to their remuneration and terms of employment. The committee will also make recommendations to the Board on proposals for the granting of share options and other equity incentives pursuant to the New LTIP or any equity incentive scheme in operation from time to time. The committee will meet as and when necessary (and in any event, not less than twice a year). In exercising this role, the New Board shall have regard to the recommendations put forward in the UK Corporate Governance Code. The remuneration committee will, on Admission, comprise Tan Sri Abi Musa, who will act as chairman of the committee, Alan Cleverly and Patrick Howes.

The Board has adopted a share dealing code as part of taking all reasonable steps to ensure compliance by the New Board and the Company's applicable employees with AIM Rule 21 and other applicable regulations.


15. Takeover Code
The Takeover Code does not currently apply to the Company and is not expected to apply to the Company following Admission, on the basis that (a) no securities of the Company will be admitted to trading on a regulated market in the UK (AIM is not a regulated market for these purposes) or on any stock exchange in the Channel Islands or Isle of Man and (b) the Company's place of central management and control is not




26

expected to be in the UK, the Channel Islands or the Isle of Man. This is known as the "residency exemption".

For this reason Shareholders will not be offered any protections under the Takeover Code. It is emphasised that, although the Consolidated Ordinary Shares will trade on AIM, the Company will not be subject to takeover regulation in the UK.

It should be noted however that on 5 July 2012, the Panel released a Public Consultation Paper ("PCP") in which it proposed, inter alia, to remove the residency exemption described above in relation to the Company's place of central management, such that the resultant effect would be that the Takeover Code would apply to the Enlarged Group going forward. The consultation period for this PCP ended on 28 September 2012 and the results of the paper are expected to be published shortly.


16. Taxation
Information regarding taxation in the UK with regard to holdings of shares in the Company is set out in paragraph 13 of Part 8 of this document. These details are, however, intended only as a general guide to the current tax position under UK taxation law. Shareholders who are in any doubt as to their tax position or who are subject to tax in jurisdictions other than the UK are strongly advised to consult their own independent financial adviser immediately.


17. Admission, dealings, settlement and CREST
Application has been made to the London Stock Exchange for the Enlarged Share Capital to be admitted to trading on AIM, conditional, inter alia, upon the approval of the Resolutions at the General Meeting. It is expected that Admission will become effective and dealings will commence in the Enlarged Share Capital at
8.00 a.m. on or around 26 March 2013. No application has been or will be made for the Enlarged Share
Capital to be admitted to trading or to be listed on any other stock exchange.

The Articles permit the Company to issue ordinary shares in the Company in uncertificated form in accordance with the CREST Regulations. CREST is a paperless settlement system enabling title to securities to be evidenced otherwise than by certificate and transferred otherwise than by written instrument, in accordance with the CREST Regulations.

Settlement of transactions in the Consolidated Ordinary Shares following Admission may take place within the CREST system if Shareholders so wish. CREST is a voluntary system and holders of Shares who wish to receive and retain share certificates will be able to do so. For more information concerning CREST, Shareholders should contact their brokers or Euroclear UK & Ireland Limited at 33 Cannon Street, London EC4M 5SB.


18. Risk Factors
Shareholders should consider carefully the risk factors set out in Part 4 of this document in addition to the other information presented.


19. General Meeting
Set out at the end of this document is a notice convening the General Meeting to be held at the offices of the Company at Academy House, London Road, Camberley, Surrey GU15 3HL on 25 March 2013 at 10.00 a.m. at which the Resolutions will be proposed.

Resolutions 1 to 4 will be proposed as Ordinary Resolutions and seek to:

1. approve the Acquisition;

2. authorise the Directors to allot equity securities;

3. approve the New Long Term Incentive Plan; and

4. approve the Share Consolidation.




27

Resolutions 5 to 7 will be proposed as Special Resolutions and seek to:

5. disapply statutory pre-emption rights;

6. change the Company's name to Graphene NanoChem Plc; and

7. approve the amendments to the Articles.

The Resolutions are set out in full in the notice of General Meeting at the end of this document.


20. Irrevocable undertakings
The Directors have given irrevocable undertakings to the Company to vote in favour of the Resolutions to be proposed at the General Meeting (and, where relevant, to procure that such action is taken by the relevant registered holders if that is not them) in respect of their entire beneficial holdings totalling, in aggregate,
14,474,000 Existing Unconsolidated Ordinary Shares, representing approximately 8.7 per cent. of the
Existing Unconsolidated Ordinary Share Capital.

In addition, certain other Shareholders have given irrevocable undertakings to the Company to vote in favour of the Resolutions to be proposed at the General Meeting (and, where relevant, to procure that such action is taken by the relevant registered holders if that is not them) in respect of their holdings totalling, in aggregate 61,632,410 Existing Unconsolidated Ordinary Shares, representing approximately 37.0 per cent. of the Existing Unconsolidated Ordinary Share Capital.

In total, therefore, the Company has received irrevocable undertakings to vote in favour of the Resolutions to be proposed at the General Meeting in respect of holdings totalling, in aggregate, 76,106,410 Existing Unconsolidated Ordinary Shares, representing 45.7 per cent. of the Existing Unconsolidated Ordinary Share Capital.


21. Actions To Be Taken
You will find enclosed with this document a Form of Proxy for use at the General Meeting.

Whether or not Shareholders propose to attend the General Meeting in person, it is important that Shareholders complete and sign the enclosed Form of Proxy in accordance with the instructions printed thereon and return it to the Company's Registrars, Share Registrars Limited, Suite E, First Floor, 9 Lion and Lamb Yard, Farnham, Surrey GU9 7LL as soon as possible and, in any event, so as to be received not later than 10.00 a.m. on 21 March 2013. The completion and return of a Form of Proxy will enable you to vote at the General Meeting without having to be present in person but will not preclude you from attending the General Meeting and voting in person if you so wish. If a Shareholder has appointed a proxy and attends the General Meeting in person and votes, his proxy appointment will automatically be terminated and his votes in person will stand in its place.


22. Recommendation
The Directors consider that the acquisition of Platinum NanoChem by the Company is an exciting opportunity and are satisfied that the Acquisition is in the best interest of Shareholders and the Company as a whole.

Accordingly, the Directors recommend that Shareholders vote in favour of the Resolutions, as they have irrevocably undertaken to do so in respect of their entire beneficial holdings amounting to, in aggregate, 14,474,000 Existing Unconsolidated Ordinary Shares, representing approximately
8.7 per cent. of the Existing Unconsolidated Ordinary Share Capital.

Yours faithfully,

Dr Patrick Dennis Howes
Chairman

[leedskier] 09/3/2013 13:39

Talking of blue chips ... a major shareholder, holding 5.16%, of the new company and to be appointed as Non Ex Director of the new company is

Dato' Larry Gan Nyap Liou(Aged 58), Proposed Non-executive Director
Larry spent 26 years with Accenture, the world's leading consulting firm, during which time he held many global leadership roles, consulted on strategic projects for multinational corporations, and worked with innovative technologies around the world. He was Accenture's Managing Partner for Asia, and between 1999 to 2003 he managed the firm's multi-billion dollar Venture Fund in Asia Pacific and concluded investments in China, Japan, Australia and Singapore. He served as Chairman of the Association of Computer Industry Malaysia, Vice-President of the Association of Asian Oceania Computer Industry Organisation, and a Member of the Minister of Science & Technology Think Tank, Copyright Tribunal, Labuan International Financial Exchange Committee, MIMOS Berhad
(Government Technology Research) and the Malaysia US Business Council.
He is currently Chairman of Cuscapi and Diversified Gateway Solutions Berhad, and holds a number of other directorships. He is also Chairman of the British Malaysian Chamber of Commerce and a Board Member of the Minority Shareholder Watchdog Group. Larry is a chartered accountant and a certified management consultant.

Accenture is a global management consulting, technology services and outsourcing company, with approximately 259,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world's most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$27.9 billion for the fiscal year ended Aug. 31, 2012.

[rob67] 09/3/2013 13:05

Interesting that Scomi Group which is mentioned in the admission doc as a customer from July 2013 onwards is also a Malaysian company and quite a substantial one at that, with a turnover of RM 1,383,737,000 (£298,556,603) reported in last FY accounts. Good to see they have large Blue Chips already on board.

[rob67] 09/3/2013 12:48

I can verify Leed's post 199. Thx for the info.

[fillipe] 09/3/2013 11:42

leeds - thanks very much for all your work here.

f

[leedskier] 09/3/2013 08:30

I was advised overnight that there has been no change in the number of shares to be issued to the vendors. It has always been agreed as the number set out in the admission document.

If and insofar as any clarification is required as to the difference between that number and the number set-out in the Notice posted by ABT to the Malaysian Bursa last December, it is an enquiry which should be directed to them. In keeping with my usual practice, I have forwarded, unaltered, the relevant email I received this morning from BIP, to two long standing contributors to this, and earlier, BIP BBs. I do not propose to circulate it more widely.

[leedskier] 09/3/2013 07:37

Alan Cleverly is indeed ...



Alan Michael Cleverly, OBE (Aged 64), Proposed Non-executive Director
Alan currently serves as Parliamentary Agent to Rt Hon Michael Gove MP, the Secretary of State for Education, and is actively involved in various non-profit organisations in support of small and medium enterprises and corporate governance practices. Alan is the is the founder and Chief Executive Officer of the Genesis Initiative, a non-profit body that represents the interests of UK Small and Medium Enterprises. He was the former director and company secretary to the Corporate Governance Forum Limited and currently serves as Events Facilitator to the All Party Parliamentary Corporate Governance Group.

It is good to have someone in the UK just in case there are any 'difficulties' or 'misunderstandings' by those investing or indeed shorting this company.

[leedskier] 09/3/2013 07:31

From the Admission Document I learnt:

Tan Sri Dato' Sri Abi Musa Asa'ari Bin Mohamed Nor (Aged 63), Proposed Non-executive Chairman (of Graphene Nanochem)

Abi Musa joined the Platinum Board on 7 October 2006. Abi Musa has had a distinguished career in the Malaysian civil service, retiring as the Secretary General of the Ministry of Agriculture and Small Industries, Malaysia in September 2006. He started his career as an Assistant Director in the Public Service Department in 1973 and thereafter served in various capacities in the Malaysian civil service including as the Deputy Director, Petroleum Development Division under the Prime Minister's Department, Deputy Director, Budget Division of the Ministry of Finance and the Director General of the Federal Agriculture Marketing Authority, Malaysia. His current roles include serving as Non-executive Chairman of the Malaysian Pilgrimage Funds Board, with more than US$9 billion in assets under management, as Non-executive Chairman of Pelikan International, a global inks company, and as an Independent Non-executive Director of HeiTech Padu Berhad, a Malaysian ICT company listed on the Main Board of Bursa Malaysia. Abi Musa is also the Chairman of the Malaysian Biodiesel Association and of the Sultan Idris Education University. Abi Musa holds an MBA from the University of Birmingham, and an undergraduate degree in economics from the University of Malaya.


Dr Patrick Howes - Non-Ex Chairman - Patrick Howes holds a Ph.D. in Chemistry from Salford University in the synthesis and properties of a class of nanomaterials utilised in the oil and gas industries. His previous experience includes catalyst development with a joint-venture between UOP, a multi-national company developing and delivering technology to the oil and gas industries, and Johnson Matthey plc. He also worked for Laporte Industries plc, the second company in the U.K. and the Taiko Group. He is the founder of Iceni Chemicals International, a process-plant design consultancy and trading house, and a director of Natural Bleach Sdn Bhd, developing and marketing novel, environmentally-friendly clay products for the refining of edibile oils, and re-refiningof used mineral oils.

Dr ("Joe") Wong Kai Fatt (Aged 48), Chief Executive Officer
Joe Wong holds a degree in computer science and a Ph.D. in Pharmacy and Healthcare Administration (1991) from the University of Louisiana. He is currently on the board of Boots The Chemist Sdn. Bhd. and a number of other companies. Prior to this, he held a number of senior roles in the financial services sector and has published works in the area of healthcare and equity investment.

David John Long (Aged 66), Non-executive Director
David Long has had many years' experience in operational management and business accounting processes, particularly within the paints and coatings industry. He was the General Manager of Hampton Paints, the specialist paint and chemical company. Previously he was at Berger Paints and Ameron International Corporation, prior to which he spent 13 years at International Paint, now part of AKZO Nobel, the global paints and coatings business. He was Finance and Administration Director of Perfect Images Limited, a print and printing ink supplier. David Long has a degree in business management. He is currently the Chairman of the Audit Committee.

[spindok] 09/3/2013 01:18

Good luck all.. Special thanks to Leed....

[fillipe] 08/3/2013 23:10

mm - thanks.....I sort of thought that's how it should be - hopefully it will be like that.

As far as the future goes I feel that anything solid involved in "nanotech" should attract the right sort of attention.

f

[rob67] 08/3/2013 23:08

Leeds

Sorry to be the bringer of more work but looks like we'll need another new BB with the new name and ticker!!

[rob67] 08/3/2013 23:04

Reading the admission doc i believe the placing went to AXA investment managers UK as i have never seen them on the existing BIP Shareholders List.

[bam bam rubble] 08/3/2013 21:35

The last we heard -
One of Platinum Nanochem's main shareholders Asia BioEnergy Technologies said yesterday Biofutures was acquiring the entire issued share capital of Platinum Nanochem for 1.154 billion new Biofutures shares.

Todays news... Vendors: "scratch the previous deal we want 50% more. Give us 1.7 billion shares"


Bulls reaction to vendors getting almost 50% more shares than expected: Fantastic!

[leedskier] 08/3/2013 21:08

With the speciality chemicals business providing a solid foundation for the Enlarged Group, the New Board aims to maximise the opportunities presented by the Enlarged Group's ability to manufacture Graphene affordably at commercial scale. Despite the current scarcity of Graphene, the New Board has no plans for the Enlarged Group to be a volume supplier of Graphene to third parties. Instead, they will focus on the development of proprietary applications of Graphene in areas where they believe that it is possible to deploy Graphene-enhanced products in bulk, to provide solutions to pressing problems in large and high-value markets.

The New Board has identified oilfield chemicals and engineering plastics as being two core areas where enhancement with Graphene offers the possibility of creating products which have the potential to become market leaders in the near to medium term. In particular, they believe that PlatDrill, for offshore drilling, and PlatQuat, especially when allied to the Group's planned Graphene-enhanced proppant, for the growing shale oil & gas exploration market, have the potential to deliver significant high-margin revenue streams.

In order to produce the required volumes of the Group's speciality chemicals and Graphene, the New Board intends to use the proceeds of the Placing to increase the capacity of the Platinum Group's existing speciality chemicals plant from 90 to 136 million litres per annum, including for the production of commercial quantities of PlatQuat and to increase the capacity of the Platinum Group's existing advanced nanomaterials plant from 1,000 to 250,000 kg per annum. The New Board also intends to develop the Zurex Refinery into a pre-treatment plant for a new speciality chemicals plant, with associated Graphene production, in the near to medium term.